Datasheet

gp120 Antibody
CATALOG NUMBER: 4777

Availability: In stock

$0.00
Product Price Options

* Required Fields

$0.00
Specifications
Properties
Additional Info
Background

Specifications

SPECIES REACTIVITY:Virus
TESTED APPLICATIONS:ELISA, WB
APPLICATIONS:Gp120 antibody can be used for detection of gp120 by Western blot at 1 μg/mL.
USER NOTE:Optimal dilutions for each application to be determined by the researcher.
IMMUNOGEN:gp120 antibody was raised against 15 amino acids from near the center of gp120.

The immunogen is located within amino acids 470 - 520 of gp120.
HOST SPECIES:Goat

Properties

PURIFICATION:gp120 Antibody is affinity chromatography purified via peptide column.
PHYSICAL STATE:Liquid
BUFFER:gp120 Antibody is supplied in PBS containing 0.02% sodium azide.
CONCENTRATION:1 mg/mL
STORAGE CONDITIONS:gp120 antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
CLONALITY:Polyclonal
ISOTYPE:IgG
CONJUGATE:Unconjugated

Additional Info

ALTERNATE NAMES:gp120 Antibody: Envelope glycoprotein gp160
ACCESSION NO.:AAB05604
PROTEIN GI NO.:1465781
OFFICIAL SYMBOL:env
GENE ID:155971

Background

BACKGROUND:gp120 Antibody: Human immunodeficiency virus type 1 (HIV-1) entry into target cells is directed by the envelope (Env) glycoproteins, which are present on the surface of HIV-1 virion or infected cells in the form of trimers consisting of gp120/gp41 complexes. The surface subunit, gp120, initiates the entry process by interacting sequentially with the CD4 receptor and a co-receptor CCR5 or CXCR4, thereby inducing a conformational change that allows the transmembrane (TM) gp41 subunit to mediate fusion between viral and target cell membranes. Cleavage of Env into its gp120 and gp41 components is necessary for activation of its fusogenic activity.
REFERENCES: 1) Pinter A. Roles of HIV-1 Env variable regions in viral neutralization and vaccine development. Curr. HIV Res.2007; 5:542-53.
2) Alkhatib G and Berger EA. HIV coreceptors: from discovery and designation to new paradigms and promise. Eur. J. Med. Res.2007; 12:375-84.

For Research Use Only